Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- PESTLE Analysis
- Political
- Economic
- Social
- Technological
- Legal
- Environmental
- Porter's Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential of New Entrants
- Competition in the Industry
- Threat of Substitutes
- R&D and Regulatory Approval
- The Drug Development Process
- Drug Discovery
- Preclinical Development
- Clinical Trials
- The New Drug Application Review
- NDA Data Review
- Clinical Trials for Theranostics
- Steps Followed for Radiotherapeutics in Clinical Trials
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Theranostics Replacing Conventional Treatment
- Increased Application of Theranostics in Drug Discovery
- Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
- New Radiotheranostics Driving the Theranostics Market
- Rise in Chronic Inflammatory Diseases
- Cancer Epidemics in Developing Countries
- Market Restraints
- High Cost of Theranostics
- Market Challenges
- Nanotheranostics-Bio Interactions
- Challenges of Radiotheranostics
- Failure of Radiotherapeutics
- Market Opportunities
- Theranostics in Cardiovascular Diseases
Chapter 4 Emerging Technologies and Developments
- Artificial Intelligence in Theranostics
- Drug Delivery Using Innovative Material
- Boron Neutron Capture Therapy (BNCT)
- Luminogen Aggregation-Induced Emission (AIE)
- Theranostics in Rheumatoid Arthritis (RA)
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Product Type
- Theranostics Equipment
- Theranostics Agents
- Diagnostics Theranostics Agents
- Therapeutics Theranostics Agents
- Market Analysis, by Application
- Etiology of Cancer
- Cancer Diagnosis
- Cancer Therapeutics
- Prostate Cancer
- Neuroendocrine Tumors
- Thyroid Cancer
- Neuroblastoma
- Other Diseases
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Strategic Analysis
- Clinical Trials Analysis
Chapter 7 Sustainability in Theranostics Market: An ESG Perspective
- Introduction to ESG
- Key ESG Issues in the Theranostics Market
- Safety of Personnel
- Disposal of Radioactive Waste
- Nanopollution
- Current Status of ESG in the Theranostics Market
- ESG Performance Analysis
- Concluding Remark
List of Tables
Summary Table: Global Market for Theranostics, by Product Type, Through 2029
Table 1: Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2: Worldwide Regulatory Authorities, 2024
Table 3: Dosimetry Pre-therapy and Post-therapy
Table 4: Global Market for Theranostics, by Product Type, Through 2029
Table 5: Global Market for Theranostics Equipment, by Type, Through 2029
Table 6: Global Market for Theranostics Equipment, by Region, Through 2029
Table 7: Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8: Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9: Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10: Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11: Global Market for Theranostics Agents, by Type, Through 2029
Table 12: Global Market for Theranostics Agents, by Region, Through 2029
Table 13: Select Theranostics Pair
Table 14: Properties of Commonly Used Radionuclides in Theranostics
Table 15: Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16: Difference Between Alpha Particles and Beta Particles
Table 17: Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18: Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19: Advantages and Disadvantages of Various Cancer Treatments
Table 20: Global Market for Theranostics Applications, by Type, Through 2029
Table 21: Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22: Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23: Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24: Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25: Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26: Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27: North American Market for Theranostics, by Product Type, Through 2029
Table 28: North American Market for Theranostics Equipment, by Type, Through 2029
Table 29: North American Market for Theranostics Agents, by Type, Through 2029
Table 30: North American Market for Theranostics Applications, by Type, Through 2029
Table 31: North American Market for Theranostics, by Country, Through 2029
Table 32: Theranostics Centers Needed in the U.S.
Table 33: European Market for Theranostics, by Product Type, Through 2029
Table 34: European Market for Theranostics Equipment, by Type, Through 2029
Table 35: European Market for Theranostics Agents, by Type, Through 2029
Table 36: European Market for Theranostics Applications, by Type, Through 2029
Table 37: European Market for Theranostics, by Country, Through 2029
Table 38: Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39: Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40: Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41: Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42: Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43: Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44: Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45: Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46: Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47: Market Ranking, Theranostics Agents
Table 48: Strategic Analysis: Theranostics Market, 2021-2024
Table 49: Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50: The Three Pillars of ESG
Table 51: ESG Ranking of Leading Theranostics Players
Table 52: ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53: Report Information Sources
Table 54: Major Acronyms Used in the Global Theranostics Market
Table 55: Bayer AG: Company Snapshot
Table 56: Bayer AG: Financial Performance, FY 2022 and 2023
Table 57: Bayer AG: Product Portfolio
Table 58: Bayer AG: News/Key Developments, 2021-2023
Table 59: Curium Pharma: Company Snapshot
Table 60: Curium Pharma: Product Portfolio
Table 61: GE Healthcare: Company Snapshot
Table 62: GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63: GE Healthcare: Product Portfolio
Table 64: GE Healthcare: News/Key Developments, 2023-2024
Table 65: Lantheus: Company Snapshot
Table 66: Lantheus: Financial Performance, FY 2022 and 2023
Table 67: Lantheus: Product Portfolio
Table 68: Lantheus: News/Key Developments, 2023-2024
Table 69: Novartis AG: Company Snapshot
Table 70: Novartis AG: Financial Performance, FY 2022 and 2023
Table 71: Novartis AG: Product Portfolio
Table 72: Novartis AG: News/Key Developments, 2022
Table 73: Siemens Healthineers AG: Company Snapshot
Table 74: Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75: Siemens Healthineers AG: Product Portfolio
Table 76: Siemens Healthineers AG: News/Key Developments, 2022
Table 77: Telix Pharmaceutical Ltd.: Company Snapshot
Table 78: Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79: Telix Pharmaceutical Ltd.: Product Portfolio
Table 80: Telix Pharmaceutical Ltd.: News/Key Developments, 2022-2024
Table 81: Upcoming Startups in The Field of Theranostics
List of Figures
Summary Figure: Global Market for Theranostics, by Product Type, 2021-2029
Figure 1: Theranostics Workflow
Figure 2: Components of the Drug Approval Process
Figure 3: Preclinical and Clinical Trials Phases
Figure 4: Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5: Market Dynamics of Theranostics
Figure 6: Disadvantages of Chemotherapy Treatment
Figure 7: Drug Development Cost, 2002 and 2022
Figure 8: Global Market Shares of Theranostics, by Product Type, 2023
Figure 9: Global Market Shares of Theranostics, by Product Type, 2029
Figure 10: Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11: Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12: Schematic Representation of Radionuclide Therapy
Figure 13: Schematic Representation of Radionuclide Therapy
Figure 14: Etiology of Cancer
Figure 15: Cancer Diagnostics Methods
Figure 16: Types of Imaging
Figure 17: Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18: Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19: Share of Clinical Trials, by Recruiting Status, 2024
Figure 20: Share of Clinical Trials, by Type of Indication, 2024
Figure 21: Share of Clinical Trials, by Phase, 2024
Figure 22: Share of Clinical Trials, by Type of Funder, 2024
Figure 23: Share of Clinical Trials, by Gender, 2024
Figure 24: The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25: ESG Concerns in the Theranostics Market
Figure 26: Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27: Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28: GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29: GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30: Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31: Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32: Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35: Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023
